1246373-16-9

Basic information

• Product Name: 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide
• Synonyms: 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide
• CAS NO: 1246373-16-9
• Molecular Weight: 549.32
• Mol File: 1246373-16-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide(1246373-16-9)
• EPA Substance Registry System: 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide(1246373-16-9)

Safety Data

• Hazardous Substances Data: 1246373-16-9(Hazardous Substances Data)

Upstream product

• 1246373-15-8 5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-2-methoxypyridin-3-ylamine 
• 13918-92-8 2,4-difluorobenzene-1-sulfonyl chloride 
• 893440-50-1 2-(methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinamine 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 1083326-73-1 N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1246372-52-0 2-bromo-5-iodoimidazo[2,1-b][1,3,4]thiadiazole 

Downstream Products

• 1246373-17-0 2,4-difluoro-N-[2-methoxy-5-(5-pyridazin-4-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide 
• 1337919-08-0 2,4-difluoro-N-[2-methoxy-5-(5-methyl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]benzenesulfonamide 

Relevant articles and documents

IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS

There is provided compounds of formula (I): wherein R1 R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, mTOR and/or Flt3) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.